Deepika Pakianathan - Net Worth and Insider Trading

Deepika Pakianathan Net Worth

The estimated net worth of Deepika Pakianathan is at least $2 Million dollars as of 2024-12-26. Deepika Pakianathan is the Director of OncoMed Pharmaceuticals Inc and owns about 2,010,542 shares of OncoMed Pharmaceuticals Inc (OMED) stock worth over $2 Million. Deepika Pakianathan is the Director of Calithera Biosciences Inc and owns about 0 shares of Calithera Biosciences Inc (CALA) stock worth over $0. Deepika Pakianathan is also the Director of Karyopharm Therapeutics Inc and owns about 0 shares of Karyopharm Therapeutics Inc (KPTI) stock worth over $0. Besides these, Deepika Pakianathan also holds Mereo BioPharma Group PLC (MREO) . Details can be seen in Deepika Pakianathan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Deepika Pakianathan has not made any transactions after 2024-08-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Deepika Pakianathan

Deepika Pakianathan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Deepika Pakianathan owns 12 companies in total, including FS Development Corp (FSDC) , Theravance Biopharma Inc (TBPH) , and Calithera Biosciences Inc (CALA) among others .

Click here to see the complete history of Deepika Pakianathan’s form 4 insider trades.

Insider Ownership Summary of Deepika Pakianathan

Ticker	Comapny	Transaction Date	Type of Owner
FSDC	FS Development Corp	2020-08-11	director
TBPH	Theravance Biopharma Inc	2020-07-01	director
CALA	Calithera Biosciences Inc	2023-01-27	director & 10 percent owner
		2024-06-07	director
		2019-04-23	director
		2018-05-23	director
		2016-06-21	director
		2016-03-17	10 percent owner
		2016-02-03	10 percent owner
		2013-11-13	10 percent owner
		2020-08-11	director
		2021-02-16	director

Deepika Pakianathan Latest Holdings Summary

Deepika Pakianathan currently owns a total of 4 stocks. Among these stocks, Deepika Pakianathan owns 2,010,542 shares of OncoMed Pharmaceuticals Inc (OMED) as of August 21, 2014, with a value of $2 Million and a weighting of 100%. Deepika Pakianathan owns 0 shares of Calithera Biosciences Inc (CALA) as of January 27, 2023, with a value of $0 and a weighting of 0%. Deepika Pakianathan also owns 0 shares of Karyopharm Therapeutics Inc (KPTI) as of June 7, 2024, with a value of $0 and a weighting of 0%. The other 1 stocks Mereo BioPharma Group PLC (MREO) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Deepika Pakianathan

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
OMED	OncoMed Pharmaceuticals Inc	2014-08-21	2,010,542	0.89	1,789,382
CALA	Calithera Biosciences Inc	2023-01-27	0	0.00	0
KPTI	Karyopharm Therapeutics Inc	2024-06-07	0	0.60	0
MREO	Mereo BioPharma Group PLC	2024-08-22	0	3.77	0

Holding Weightings of Deepika Pakianathan

Deepika Pakianathan Form 4 Trading Tracker

According to the SEC Form 4 filings, Deepika Pakianathan has made a total of 0 transactions in OncoMed Pharmaceuticals Inc (OMED) over the past 5 years. The most-recent trade in OncoMed Pharmaceuticals Inc is the acquisition of 80,203 shares on August 21, 2014, which cost Deepika Pakianathan around $2 Million.

According to the SEC Form 4 filings, Deepika Pakianathan has made a total of 1 transactions in Calithera Biosciences Inc (CALA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Calithera Biosciences Inc is the sale of 121,333 shares on January 27, 2023, which brought Deepika Pakianathan around $47,320.

According to the SEC Form 4 filings, Deepika Pakianathan has made a total of 3 transactions in Karyopharm Therapeutics Inc (KPTI) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Karyopharm Therapeutics Inc is the sale of 818,044 shares on June 7, 2024, which brought Deepika Pakianathan around $785,322.

More details on Deepika Pakianathan's insider transactions can be found in the Insider Trading History of Deepika Pakianathan table.

Insider Trading History of Deepika Pakianathan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Deepika Pakianathan Trading Performance

GuruFocus tracks the stock performance after each of Deepika Pakianathan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Deepika Pakianathan is 32.52%. GuruFocus also compares Deepika Pakianathan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Deepika Pakianathan within 3 months outperforms 3 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Deepika Pakianathan's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Deepika Pakianathan

Average Return

Average return per transaction

Outperforming Transactions

2 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	7.54
Relative Return to S&P 500(%)	6.81

Deepika Pakianathan Ownership Network

Ownership Network List of Deepika Pakianathan

No Data

Ownership Network Relation of Deepika Pakianathan

Deepika Pakianathan Owned Company Details

What does FS Development Corp do?

Who are the key executives at FS Development Corp?

Deepika Pakianathan is the director of FS Development Corp. Other key executives at FS Development Corp include director & 10 percent owner & President & CEO James B. Tananbaum , 10 percent owner Foresite Capital Fund V, L.p. , and 10 percent owner Foresite Capital Management V, Llc .

FS Development Corp (FSDC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of FS Development Corp (FSDC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of FS Development Corp (FSDC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

FS Development Corp (FSDC)'s detailed insider trading history can be found in Insider Trading Tracker table.

FS Development Corp Insider Transactions

No Available Data

What does Theravance Biopharma Inc do?

Who are the key executives at Theravance Biopharma Inc?

Deepika Pakianathan is the director of Theravance Biopharma Inc. Other key executives at Theravance Biopharma Inc include SVP & Comm & Medical Affairs Rhonda Farnum , 10 percent owner Eli Samaha , and SVP & Development Richard A Graham .

Theravance Biopharma Inc (TBPH) Insider Trades Summary

Over the past 18 months, Deepika Pakianathan made no insider transaction in Theravance Biopharma Inc (TBPH). Other recent insider transactions involving Theravance Biopharma Inc (TBPH) include a net sale of 12,439 shares made by Rhonda Farnum , a net sale of 12,090 shares made by Richard A Graham , and a net purchase of 2,498,924 shares made by Eli Samaha .

In summary, during the past 3 months, insiders sold 4,000 shares of Theravance Biopharma Inc (TBPH) in total and bought 0 shares, with a net sale of 4,000 shares. During the past 18 months, 24,529 shares of Theravance Biopharma Inc (TBPH) were sold and 2,498,924 shares were bought by its insiders, resulting in a net purchase of 2,474,395 shares.

Theravance Biopharma Inc (TBPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Theravance Biopharma Inc Insider Transactions

No Available Data

What does Calithera Biosciences Inc do?

Who are the key executives at Calithera Biosciences Inc?

Deepika Pakianathan is the director & 10 percent owner of Calithera Biosciences Inc. Other key executives at Calithera Biosciences Inc include 10 percent owner Takeda Ventures, Inc. , SR. VP & CLINICAL DEVELOPMENT Keith Orford , and SR. VP & DEVELOPMENT Christopher Molineaux .

Calithera Biosciences Inc (CALA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Calithera Biosciences Inc (CALA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Calithera Biosciences Inc (CALA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Calithera Biosciences Inc (CALA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Calithera Biosciences Inc Insider Transactions

No Available Data

What does Karyopharm Therapeutics Inc do?

Who are the key executives at Karyopharm Therapeutics Inc?

Deepika Pakianathan is the director of Karyopharm Therapeutics Inc. Other key executives at Karyopharm Therapeutics Inc include director & President and CEO Richard A. Paulson , EVP & CFO & Treasurer Michael Mason , and SVP Sales & Commercial Ops Sohanya Roshan Cheng .

Karyopharm Therapeutics Inc (KPTI) Insider Trades Summary

Over the past 18 months, Deepika Pakianathan made 2 insider transaction in Karyopharm Therapeutics Inc (KPTI) with a net sale of 1,724,222. Other recent insider transactions involving Karyopharm Therapeutics Inc (KPTI) include a net sale of 165,766 shares made by Richard A. Paulson , a net sale of 55,214 shares made by Michael Mason , and a net sale of 34,041 shares made by Stuart Poulton .

In summary, during the past 3 months, insiders sold 10,902 shares of Karyopharm Therapeutics Inc (KPTI) in total and bought 0 shares, with a net sale of 10,902 shares. During the past 18 months, 2,075,796 shares of Karyopharm Therapeutics Inc (KPTI) were sold and 41,140 shares were bought by its insiders, resulting in a net sale of 2,034,656 shares.

Karyopharm Therapeutics Inc (KPTI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Karyopharm Therapeutics Inc Insider Transactions

No Available Data

What does OncoMed Pharmaceuticals Inc do?

Who are the key executives at OncoMed Pharmaceuticals Inc?

Deepika Pakianathan is the director of OncoMed Pharmaceuticals Inc. Other key executives at OncoMed Pharmaceuticals Inc include See Remarks Sunil Patel , Chairman & CEO Paul J Hastings , and SVP & Chief Medical Officer Jakob Dupont .

OncoMed Pharmaceuticals Inc (OMED) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of OncoMed Pharmaceuticals Inc (OMED) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of OncoMed Pharmaceuticals Inc (OMED) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

OncoMed Pharmaceuticals Inc (OMED)'s detailed insider trading history can be found in Insider Trading Tracker table.

OncoMed Pharmaceuticals Inc Insider Transactions

No Available Data

What does Alder BioPharmaceuticals Inc do?

Who are the key executives at Alder BioPharmaceuticals Inc?

Deepika Pakianathan is the director of Alder BioPharmaceuticals Inc. Other key executives at Alder BioPharmaceuticals Inc include 10 percent owner H Lundbeck A S , Chief Medical Officer Paul Streck , and Chief Financial Officer Carlos Campoy .

Alder BioPharmaceuticals Inc (ALDR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Alder BioPharmaceuticals Inc (ALDR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Alder BioPharmaceuticals Inc (ALDR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Alder BioPharmaceuticals Inc (ALDR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alder BioPharmaceuticals Inc Insider Transactions

No Available Data

What does Alexza Pharmaceuticals Inc do?

Who are the key executives at Alexza Pharmaceuticals Inc?

Deepika Pakianathan is the director of Alexza Pharmaceuticals Inc. Other key executives at Alexza Pharmaceuticals Inc include director & President & CEO Thomas Braxton King , Former SVP & CFO & Secretary Mark K Oki , and EVP & Operations & COO Robert A Lippe .

Alexza Pharmaceuticals Inc (ALXA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Alexza Pharmaceuticals Inc (ALXA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Alexza Pharmaceuticals Inc (ALXA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Alexza Pharmaceuticals Inc (ALXA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alexza Pharmaceuticals Inc Insider Transactions

No Available Data

What does Senseonics Holdings Inc do?

Who are the key executives at Senseonics Holdings Inc?

Deepika Pakianathan is the 10 percent owner of Senseonics Holdings Inc. Other key executives at Senseonics Holdings Inc include Chief Financial Officer Frederick T. Sullivan , director & President & Chief Exec Officer Timothy T Goodnow , and VP Operations & Qual & Reg Mukul Jain .

Senseonics Holdings Inc (SENS) Insider Trades Summary

Over the past 18 months, Deepika Pakianathan made no insider transaction in Senseonics Holdings Inc (SENS). Other recent insider transactions involving Senseonics Holdings Inc (SENS) include a net purchase of 700,000 shares made by Douglas A Roeder , a net purchase of 315,000 shares made by Timothy T Goodnow , and a net purchase of 124,933 shares made by Frederick T. Sullivan .

In summary, during the past 3 months, insiders sold 0 shares of Senseonics Holdings Inc (SENS) in total and bought 839,933 shares, with a net purchase of 839,933 shares. During the past 18 months, 30,889 shares of Senseonics Holdings Inc (SENS) were sold and 1,139,933 shares were bought by its insiders, resulting in a net purchase of 1,109,044 shares.

Senseonics Holdings Inc (SENS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Senseonics Holdings Inc Insider Transactions

No Available Data

What does TriVascular Technologies Inc do?

Who are the key executives at TriVascular Technologies Inc?

Deepika Pakianathan is the 10 percent owner of TriVascular Technologies Inc. Other key executives at TriVascular Technologies Inc include 10 percent owner Krishna Kittu Kolluri , VP & Gen. Counsel and Secretary Kimberley A. Elting , and Chief Technology Officer Michael V. Chobotov .

TriVascular Technologies Inc (TRIV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TriVascular Technologies Inc (TRIV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TriVascular Technologies Inc (TRIV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TriVascular Technologies Inc (TRIV)'s detailed insider trading history can be found in Insider Trading Tracker table.

TriVascular Technologies Inc Insider Transactions

No Available Data

What does Tandem Diabetes Care Inc do?

Who are the key executives at Tandem Diabetes Care Inc?

Deepika Pakianathan is the 10 percent owner of Tandem Diabetes Care Inc. Other key executives at Tandem Diabetes Care Inc include director & PRESIDENT AND CEO Kim D Blickenstaff , SVP & General Counsel Shannon Marie Hansen , and Senior Vice President and CFO Leigh Vosseller .

Tandem Diabetes Care Inc (TNDM) Insider Trades Summary

Over the past 18 months, Deepika Pakianathan made no insider transaction in Tandem Diabetes Care Inc (TNDM). Other recent insider transactions involving Tandem Diabetes Care Inc (TNDM) include a net sale of 0 shares made by Dick Allen , a net sale of 40,000 shares made by Kim D Blickenstaff , and a net purchase of 6,200 shares made by Leigh Vosseller .

In summary, during the past 3 months, insiders sold 40,000 shares of Tandem Diabetes Care Inc (TNDM) in total and bought 532 shares, with a net sale of 39,468 shares. During the past 18 months, 45,000 shares of Tandem Diabetes Care Inc (TNDM) were sold and 14,667 shares were bought by its insiders, resulting in a net sale of 30,333 shares.

Tandem Diabetes Care Inc (TNDM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tandem Diabetes Care Inc Insider Transactions

No Available Data

What does Disc Medicine Inc do?

Who are the key executives at Disc Medicine Inc?

Deepika Pakianathan is the director of Disc Medicine Inc. Other key executives at Disc Medicine Inc include director & Chief Executive Officer John D Quisel , Chief Medical Officer William Jacob Savage , and director & 10 percent owner Orbimed Advisors Llc .

Disc Medicine Inc (IRON) Insider Trades Summary

Over the past 18 months, Deepika Pakianathan made no insider transaction in Disc Medicine Inc (IRON). Other recent insider transactions involving Disc Medicine Inc (IRON) include a net sale of 50,083 shares made by William Richard White , a net sale of 46,666 shares made by William Jacob Savage , and a net sale of 75,429 shares made by Kevin Bitterman .

In summary, during the past 3 months, insiders sold 45,627 shares of Disc Medicine Inc (IRON) in total and bought 0 shares, with a net sale of 45,627 shares. During the past 18 months, 3,952,810 shares of Disc Medicine Inc (IRON) were sold and 388,891 shares were bought by its insiders, resulting in a net sale of 3,563,919 shares.

Disc Medicine Inc (IRON)'s detailed insider trading history can be found in Insider Trading Tracker table.

Disc Medicine Inc Insider Transactions

No Available Data

What does Pardes Biosciences Inc do?

Who are the key executives at Pardes Biosciences Inc?

Deepika Pakianathan is the director of Pardes Biosciences Inc. Other key executives at Pardes Biosciences Inc include 10 percent owner Fs Development Holdings Ii, Llc , 10 percent owner Foresite Capital Fund V, L.p. , and 10 percent owner Foresite Capital Opportunity Fund V, L.p. .

Pardes Biosciences Inc (PRDS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Pardes Biosciences Inc (PRDS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pardes Biosciences Inc (PRDS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Pardes Biosciences Inc (PRDS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pardes Biosciences Inc Insider Transactions

No Available Data

Deepika Pakianathan Mailing Address

Above is the net worth, insider trading, and ownership report for Deepika Pakianathan. You might contact Deepika Pakianathan via mailing address: 160 Bovet Road, Suite 408, C/o Delphi Ventures, San Mateo Ca 94402.

Discussions on Deepika Pakianathan

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.